"Samples of R327 have been received by ACDP with testing expected to start in September and take a number of months. All intellectual property rights are retained by the Company"
As discussed earlier CSIRO listed as fee for service and don't seem to be in any rush to get this through. Screams out that if someone was in a contact zone and has to isolate something like this could be invaluable. Could quite possibly even have use against standard flu as mentioned in early data as an off the shelf treatment to reduce viral load?
It just seems so strange how CSIRO keep looking "for a fee" but no excitement or usable results, and no real rush. Even more bizarre is recce seemed to suggest the 529 anti viral version should be more suitable yet it appeared dohertys/CSIRO Didn't even want to consider that?? What gives?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)